ALKIVIA Phase III Win Opens Myositis Franchise, But Payer Ceiling and Data Gaps Cap Commercial Upside

Argenx's Vyvgart Hytrulo Achieves Phase III Primary Endpoint in Autoimmune Myositis

Argenx announced positive Phase III results for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis, specifically immune-mediated necrotising myopathy (IMNM) and dermatomyositis (DM). The ALKIVIA trial (NCT05523167) met its primary endpoint, demonstrating a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) compared to placebo after 52 weeks. This clinical success led to an 8.9% rise in Argenx's stock on the Nasdaq exchange.

• The Phase III ALKIVIA trial demonstrated that Vyvgart Hytrulo achieved its primary endpoint in the combined IMNM and DM population, showing a statistically significant 15.4-point improvement in mean Total Improvement Score (TIS) over placebo after 52 weeks. Improvements were observed as early as four weeks and sustained throughout the year, even with steroid tapering, with all six core set measures contributing positively.
• In separate subtype analyses, the primary endpoint was met in the IMNM cohort, while the DM cohort showed clinically meaningful benefit, though not statistical significance. The drug's safety profile in the ALKIVIA study was consistent with previous investigations, reinforcing its tolerability for patients with these rare autoimmune conditions.
• Following the positive trial results, Argenx's stock surged by 8.9% on the Nasdaq exchange, reflecting investor confidence in Vyvgart Hytrulo's potential. The company, with a market cap of $61.25bn, is also exploring the drug for other autoimmune rheumatologic diseases and has prior FDA approvals for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

Vyvgart Hytrulo's ALKIVIA Trial Success in Autoimmune Myositis

Several recent studies have evaluated therapeutic interventions across the spectrum of autoimmune myositis, providing critical safety and efficacy data. In a Cochrane-level analysis of rituximab (a B-cell depleting anti-CD20 monoclonal antibody) in idiopathic inflammatory myopathies, efficacy outcomes assessed using the IMACS Definitions of Improvement (IMACS DOI) yielded uncertain results at eight weeks (RR 0.72, 95% CI 0.39–1.34; n=200), though among patients achieving at least minimal improvement, 95% showed gains in muscle-related measures and 84% in patient-reported outcomes. Safety data from the randomised period were not extractable, and evidence on withdrawals due to adverse events or lack of benefit remained very uncertain (RR 1.47, 95% CI 0.25–8.59; n=190). Similarly, abatacept (a T-cell co-stimulation inhibitor) demonstrated little to no meaningful effect on the HAQ-DI (MD −0.14, 95% CI −0.29 to 0.02; n=147) or MMT8 muscle strength scores (MD 3.6, 95% CI −0.15 to 7.35), although IMACS DOI achievement at three to six months may favour abatacept (RR 1.42, 95% CI 1.02–1.98; n=167), with serious adverse event and withdrawal data both remaining very uncertain.

In an open-label pilot study of tofacitinib 11 mg extended-release daily — a JAK inhibitor — in refractory dermatomyositis (n=10), the primary endpoint was met in all subjects at 12 weeks. Half of participants achieved moderate improvement and the remaining half achieved minimal improvement per 2016 ACR/EULAR myositis response criteria. Mean CDASI activity scores declined significantly from 28 ± 15.4 at baseline to 9.5 ± 8.5 at week 12 (P=0.0005), accompanied by statistically significant reductions in serum CXCL9/CXCL10 chemokine levels and marked suppression of STAT1 signalling with downregulation of interferon target gene expression in skin biopsy samples from three of nine evaluable patients. Specific adverse event details were not fully reported in available data.

Evidence supporting intravenous immunoglobulin (IVIg) in refractory idiopathic inflammatory myopathies is comparatively robust. IVIg probably improves disability (SMD 0.86, 95% CI 0.51–1.21; n=136) and muscle strength (SMD 0.78, 95% CI 0.43–1.13; n=136), with a higher ACR/EULAR response rate versus placebo (RR 1.80, 95% CI 1.26–2.56; n=95). In refractory dermatomyositis specifically, IVIg significantly improved skin symptoms as measured by the CDASI total activity score (MD −8.20, 95% CI −11.91 to −4.49; n=95). From a safety perspective, IVIg may be associated with a greater incidence of serious adverse events compared to placebo (RR 1.91, 95% CI 0.50–7.30; n=144), though withdrawal rates due to adverse events or lack of efficacy showed little to no difference between groups (RR 1.02, 95% CI 0.24–4.33; n=154).

Addressing Unmet Needs in Autoimmune Myositis Treatment

Current treatment approaches for autoimmune myositis are constrained by a combination of biological complexity, limited evidence, and significant heterogeneity across disease subtypes. These factors collectively impede the development of standardized, effective therapeutic strategies and contribute to suboptimal patient outcomes across the myositis spectrum.

• Treatment resistance and refractory disease: Sporadic inclusion body myositis is characterized by near-complete resistance to immunosuppressive therapy, with failure across all available immunosuppressive agents. This lack of efficacy reflects an incomplete understanding of the molecular mechanisms sustaining inflammatory tissue damage in affected patients.

• Glucocorticoid limitations: Glucocorticoids remain the empirical first-line standard of care despite a well-documented adverse effect profile. Treatment regimens combining glucocorticoids with other immunosuppressive or immunomodulating agents frequently fail to achieve sustained clinical benefit, and long-term tolerability remains a significant concern.

• Insufficient evidence base: No controlled, double-blind trials have demonstrated the superiority of one immunosuppressant over another in this setting. Although rituximab has shown efficacy in retrospective studies and open-label trials, findings are limited by inadequate statistical power.

• Diagnostic complexity: Bohan and Peter's diagnostic criteria demonstrate sensitivity of 74–100% but low specificity, owing to poor differentiation of polymyositis from other neuromuscular diseases. Accurate diagnosis requires a complete autoantibody profile alongside muscle biopsy to correctly classify distinct clinical entities and define their respective prognoses.

• Variable treatment response: The broad variation in clinical manifestations across idiopathic inflammatory myopathies reflects distinct underlying pathophysiological mechanisms. Treatment response and prognosis are meaningfully associated with myositis-specific antibody profiles, with additional racial differences observed.

• Poor prognosis in high-risk subtypes: Immune-mediated necrotizing myopathy carries a refractory phenotype and worse overall prognosis. Rapidly progressive interstitial lung disease remains particularly lethal, with a mortality rate of approximately 30% despite early intensive therapy with corticosteroids and multiple immunosuppressants.